Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Generex and Acertus to develop oral recombinant human growth hormone

Dec. 17, 2003

Sumitomo patents new series of DPP-IV inhibitors

Dec. 16, 2003

Dosing complete in phase I Oxycyte study

Dec. 16, 2003

deCODE isolates new obesity genes

Dec. 16, 2003

Topline results from pivotal Metformin GR study

Dec. 16, 2003

Promising new antisickling agent 5-HMF: in vitro and in vivo studies

Dec. 15, 2003

New bombesin antagonists and their use in sexual disorders reported by Pfizer

Dec. 15, 2003

ThGRF does not improve functional recovery following hip fracture surgery

Dec. 15, 2003

Encouraging preclinical results for BioSante's BioAir CAP-delivered insulin

Dec. 15, 2003

Fluoxetine safe and effective for adolescents with bulimia nervosa

Dec. 11, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....